Know Cancer

forgot password

Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neo-adjuvant Treatment in Patients With Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)

Phase 2
18 Years
Open (Enrolling)
Primary Breast Cancer

Thank you

Trial Information

Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neo-adjuvant Treatment in Patients With Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)

Primary Objective To compare the pathologic complete response (pCR) rate in the breast
(ypT0/is ypN0/+) in patients with operable Triple Negative or luminal B/HER2 normal breast
cancer treated with either cabazitaxel or weekly paclitaxel.

Secondary Objective To assess

- pCR rates per arm separately for the stratified subpopulations.

- Objective response rate (ORR) in the breast according to WHO criteria.

- pCR rate defined as ypT0 ypN0.

- pCR rate defined as ypT0/is ypN0.

- pCR rate in the axillary lymph nodes (ypN0).

- To determine the pCR rate and local recurrence free survival (LRFS) in patients with a
clinical complete response (cCR) and a negative core biopsy before surgery.

- Breast conservation surgery rate.

- To assess the toxicity (NCI CTCAE V4.03) and compliance in both arms.

- Invasive loco-regional recurrence free survival (LRRFS), distant-disease-free survival
(DDFS), invasive disease-free survival (IDFS), and overall survival (OS).

- To explore the biomarkers and profiles potentially predicting response to treatment.

Inclusion Criteria:

- Written informed consent for all study according to local regulatory requirements
prior to beginning specific protocol procedures.

- Complete baseline documentation must be sent to GBG Forschungs GmbH.

- Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by
core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not
allowed. In case of bilateral cancer, the investigator has to decide prospectively
which side will be evaluated for the primary endpoint.

- Tumor lesion in the breast with a palpable size of >= 2 cm or a sonographical size of
>= 1 cm in maximum diameter. The lesion has to be measurable in two dimensions,
preferably by sonography.

- Patients must be in the following stages of disease: cT3 or cT2 or cT1c and cN+ or
cT1c and pNSLN+.

- In patients with multifocal or multicentric breast cancer, the largest lesion should
be evaluated.

- Centrally confirmed triple negative or luminal B/HER2-normal subtype. ER- and
PgR-negative defined as <1% stained cells. HER-2 negative defined as IHC 0+, 1+ or
IHC 2+ and FISH/SISH/CISH (ratio <2.0) negative. Luminal B defined as ER and/or PgR +
and > 14% Ki-67 stained cells. The formalin-fixed, paraffin-embedded (FFPE) breast
tissue block from the diagnostic core biopsy has therefore to be sent to the Dept. of
Pathology at the Charité, Berlin prior to randomization.

- Age >= 18 years.

- Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1 (see Appendix

- Laboratory requirements: Hemoglobin > 9.0 g/dL, Absolute neutrophil count > 1.5 x
109/L, Platelet count > 100 x 109/L, AST/SGOT and/or ALT/SGPT < 2.5 x ULN; Total
bilirubin < 1.0 x ULN, Serum creatinine < 1.5 x ULN. If creatinine 1.0 - 1.5 x ULN,
creatinine clearance will be calculated according to CKD-EPI formula and patients
with creatinine clearance < 60 mL/min should be excluded (see Appendix 2 for

- Negative pregnancy test (urine or serum) within 14 days prior to randomization for
all women of childbearing potential.

- Complete staging work-up within 3 months prior to randomization. All patients must
have bilateral mammography, breast ultrasound (<= 21 days), breast MRI (optional),
chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan
done. In case of positive bone scan, bone X-ray is mandatory. Other tests may be
performed as clinically indicated.

- Patients must be available and compliant for central diagnostics, treatment and

Exclusion Criteria:

- Any prior treatment for primary breast cancer including radiation therapy

- History of ipsi/ or contra-lateral invasive breast cancer

- Locally advanced disease including N3 and metastatic disease

- Patients in the following stages of disease are not allowed: cT4

- Prior malignancy without being disease-free for more than 5 years (except carcinoma
in situ of the cervix or other in situ cancer (e.g. bladder cancer) and adequately
treated basal cell carcinoma of the skin.

- Clinically significant (i.e. active) cardiovascular disease, including
cerebrovascular accident (≤6 months before enrolment), myocardial infarction,
arterial thrombotic events (≤6 months before enrolment), unstable angina pectoris,
New York Heart Association (NYHA) ≥ grade 2 congestive heart failure and/or
hypertension, serious cardiac arrhythmia requiring medication during the study and
that might interfere with regularity of the study treatment, or not controlled by

- Any severe acute or chronic medical condition which could impair the ability of the
patient to participate to the study or to comply with the study procedures or
interfere with interpretation of study results (such as significant neurological or
psychiatric disorders including psychotic disorders, dementia or seizures).

- Active infection.

- Sex hormones. Prior treatment must be stopped before study entry.

- Inability and unwillingness to comply with study visits, treatment, testing, and to
comply with the protocol.

- Administration of any live virus vaccine within 8 weeks preceding study entry.

- Use of any investigational agent within 30 days of administration of the first dose
of study drug or concurrent treatment on another clinical trial

- Requirement for radiation therapy concurrent with study anticancer treatment.
Patients who require breast or chest wall radiation therapy after surgery are

- Pregnancy or breastfeeding women

- Patients with childbearing potential who do not agree to use accepted and effective
method of contraception (barrier methods, intrauterine contraceptive devices,
sterilization) during the study treatment period and following a period of 6 months
after the last study drug administration.

- History of hypersensitivity (grade ≥ 3) to polysorbate 80 or any study drugs or

- Concurrent or planned treatment with potent strong inhibitors or strong inducers of
cytochrome P450 3A4/5 (a two-week wash-out period is necessary for patients who are
already on these treatments) (see Appendix 3)

- Contraindications to the use of corticosteroid treatment

- Symptomatic peripheral neuropathy grade ≥ 2 (National Cancer Institute Common
Terminology Criteria [NCI CTCAE] v.4.03).

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

pathologic complete response (pCR) rate

Outcome Time Frame:

15 months

Safety Issue:


Principal Investigator

Gunter von Minckwitz, Prof. Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Luisenkrankenhaus Düsseldorf


Germany: Federal Institute for Drugs and Medical Devices

Study ID:

GBG 74



Start Date:

February 2013

Completion Date:

June 2014

Related Keywords:

  • Primary Breast Cancer
  • German Breast Group
  • GBG Forschungs GmbH
  • GBG
  • GBG 74
  • Genevieve
  • Breast Cancer
  • Primary Breast Cancer
  • Cabazitaxel
  • Paclitaxel
  • neo-adjuvant
  • triple negative
  • luminal B
  • Breast Neoplasms